Syndrome of Inappropriate Antidiuretic Hormone Secretion and Lead Toxicity in a Child With Sickle Cell Disease and Pica. by Gupta, Akshay et al.
Lehigh Valley Health Network 
LVHN Scholarly Works 
Department of Emergency Medicine 
Syndrome of Inappropriate Antidiuretic Hormone Secretion and 




John D Lindmark 
Gillian A Beauchamp 
Follow this and additional works at: https://scholarlyworks.lvhn.org/emergency-medicine 
 Part of the Critical Care Commons, Emergency Medicine Commons, and the Pediatrics Commons 
Published In/Presented At 
Gupta, A., Amaducci, A., Koons, A., Lindmark, J. D., & Beauchamp, G. A. (2021). Syndrome of inappropriate 
antidiuretic hormone secretion and lead toxicity in a child with Sickle Cell Disease and pica. Cureus, 13(8), 
e16813. https://doi.org/10.7759/cureus.16813 
This Article is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion 
in LVHN Scholarly Works by an authorized administrator. For more information, please contact 
LibraryServices@lvhn.org. 
Received 06/08/2021 
Review began  06/22/2021 
Review ended  07/21/2021 
Published 08/01/2021
© Copyright 2021
Gupta et al. This is an open access article
distributed under the terms of the
Creative Commons Attribution License
CC-BY 4.0., which permits unrestricted
use, distribution, and reproduction in any
medium, provided the original author and
source are credited.
Syndrome of Inappropriate Antidiuretic Hormone
Secretion and Lead Toxicity in a Child With Sickle
Cell Disease and Pica
Akshay Gupta  , Alexandra Amaducci  , Andrew Koons  , John D. Lindmark  , Gillian A. Beauchamp 
1. Department of Emergency and Hospital Medicine, Lehigh Valley Health Network/University of South Florida Morsani
College of Medicine, Allentown, USA 2. Division of Medical Toxicology, Department of Emergency and Hospital
Medicine, Lehigh Valley Health Network/University of South Florida Morsani College of Medicine, Allentown, USA 3.
Department of Pediatric Critical Care, Lehigh Valley Health Network/University of South Florida Morsani College of
Medicine, Allentown, USA
Corresponding author: Gillian A. Beauchamp, gillian.beauchamp@lvhn.org
Abstract
We describe the presentation and management of a three-year-old child with a history of pica, vitamin D
deficiency, and sickle cell disease, who was admitted for pyelonephritis, and found to have elevated blood
lead level (BLL) of 103.7 µg/dL, and who subsequently developed altered mental status and syndrome of
inappropriate antidiuretic hormone secretion (SIADH). In consultation with Medical Toxicology, the patient
was chelated with calcium disodium edetate (EDTA) and British Anti Lewisite (BAL). The patient’s
hyponatremia was managed with hypertonic saline infusion. The patient’s encephalopathy improved
throughout her hospital course, and she was discharged on hospital day 8. Following five days of EDTA and
three days of BAL injections, her repeat BLL was 15.3 µg/dL. SIADH has been associated with severe lead
poisoning and may be more likely to occur in high risk patients such as individuals with sickle cell anemia,
particularly where medications are used that may cause iatrogenic hyponatremia.
Categories: Emergency Medicine, Pediatrics
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Introduction
According to The American Academy of Pediatrics, impaired cognition may be associated with a blood lead
level (BLL) greater than 5 µg/dL [1]. Significantly elevated BLL (>100 µg/dL) can result in emesis,
encephalopathy, and death. Both lead toxicity and sickle cell disease-induced vaso-occlusive crisis can
present with nausea, vomiting, constipation, abdominal pain, arthralgias, and anemia potentially leading to
challenges in diagnosis and treatment.
Hyponatremia has been reported in association with both sickle cell disease [2] and lead toxicity [3,4].
Further, hyponatremia has additionally been reported in the context of the syndrome of inappropriate
antidiuretic hormone section (SIADH) in association with lead toxicity [5,6].
We report the case of a three-year-old female with type SS sickle cell anemia who developed encephalopathy
in the context of lead toxicity and SIADH. We discuss the potentially multifactorial nature of the patient’s
SIADH including the potential contribution of sickle anemia, pica, lead toxicity, and the use of medications
associated with the development of iatrogenic hyponatremia.
This article was previously presented as a meeting abstract at the 2020 North American Congress of Clinical
Toxicology (NACCT).
Case Presentation
A three-year-old girl arrived at a community hospital emergency department (ED) with vomiting and
abdominal pain. Two days prior to presentation, the patient developed abdominal pain and generalized
malaise. She had an underlying medical history of vitamin D deficiency, functional asplenia, and type SS
sickle cell anemia with hemoglobin typically ranging between 7 and 8 g/dL. Her daily medications included
hydroxyurea, folic acid, vitamin D, and amoxicillin. Based on previous lead screening, the patient had known
mild lead elevations with the highest reported at 24 µg/dL approximately 17 months prior to her
presentation.
The ED medical team diagnosed the patient with pyelonephritis. She received intravenous (IV) ceftriaxone
and was admitted to the hospital. A whole BLL was sent due to her chronically elevated outpatient lead
concentrations. Admission laboratory studies demonstrated sodium of 141 mmol/L. She was maintained on
an IV infusion of 5% dextrose in normal saline (D5NS) due to poor oral intake. On hospital day (HD) 1, she
continued to complain of abdominal pain. An abdominal radiograph showed nonspecific gaseous distention.
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At that point, an enema and polyethylene glycol 3350 were administered. These interventions mildly
improved her stool output and oral intake. On HD 2, Escherichia coli was detected in her urine culture. After
having received a brief course of IV ceftriaxone, ciprofloxacin was initiated based on antibiotic sensitivities.
On HD 3, her repeat BLL resulted at 103.7 µg/dL prompting transfer to our toxicology center for further
treatment.
When the patient arrived at our facility, she had the following vital signs: heart rate 120 beats per minute,
blood pressure 124/73, respiratory rate 30/minute, oxygen saturation 100%, temperature 99.5 degrees
Fahrenheit. Her repeat bloodwork demonstrated: sodium 128 mmol/L, potassium 4.6 mmol/L, chloride 93
mmol/L, carbon dioxide 23 mmol/L, calcium 10.4 mg/dL, glucose 109 mg/dL, and BLL 110.2 µg/dL. The
medical toxicology service was consulted, and the patient was chelated with British Anti Lewisite (BAL)
followed by calcium disodium edetate (EDTA). She was initially continued on ciprofloxacin, D5NS
maintenance fluids, and her outpatient medications. During the evening of HD 4, the patient developed
episodic irritability and confusion. On the morning of HD 5, in the context of worsening intermittent
confusion, the repeat sodium level was 115 mmol/L. Her level of care was upgraded to pediatric intensive
care where a hypertonic saline bolus and infusion were initiated. Laboratory testing performed just prior to
initiation of hypertonic saline revealed a plasma sodium concentration of 112 mmol/L, serum osmolality of
253 mOsm/kg, urine sodium concentration of 77 mmol/L, and urine osmolality of 211 mOsm/kg.
Ciprofloxacin was discontinued and cefdinir was initiated. She had received four total doses of ciprofloxacin.
The intensive care team reduced her maintenance fluids to half of the recommended volume by weight. Her
sodium improved to 125 mmol/L within nine hours. At that point, the hypertonic saline infusion was
discontinued. Her sodium continued to rise overnight, and by the morning of HD 6, her sodium was 138
mmol/L. Given that the initial infusions of EDTA were prepared in 500 cc of 5% dextrose in water (D5W), on
HD 6, we concentrated it into 250 cc of normal saline solution to limit any unnecessary free water. The
patient’s sodium remained within normal range and her encephalopathy continued to improve until her
discharge on HD 8 when her BLL after five days of EDTA and three days of BAL was 15.3 µg/dL.
The child was seen in our toxicology clinic approximately one month later, at which point her mother
reported that she was asymptomatic. She was meeting her developmental milestones. Her BLL at that time
was 17.9 µg/dL.
Discussion
This case of a three-year-old female with type SS sickle cell anemia who developed encephalopathy in the
context of lead toxicity and SIADH, illustrates the potentially multifactorial nature of SIADH including a
history of both sickle anemia and pica, lead toxicity, and the use of medications associated with the
development of iatrogenic hyponatremia.
This patient had an elevated BLL in the context of frequent paint chip ingestion due to pica. In general, BLL
has decreased dramatically in the US over the past four decades since the elimination of lead from gasoline
paints and other consumer products, but many children still live in housing with deteriorated lead-based
paint [1]. The American Academy of Pediatrics (AAP) reports that BLL even below 5 µg/dL impair cognition
and therefore there is no safe level of lead in blood [1]. Patients that have very high BLL (>100 µg/dL) can
have significant features such as protracted vomiting and encephalopathy and even death. Elevated BLL is a
risk factor for diminished intellectual and academic abilities, higher rates of neurobehavioral disorders such
as hyperactivity and attention deficits, and lower birth weights in children. No effective treatments can
completely reduce the permanent developmental effects of lead toxicity [1].
Hyponatremia in the setting of the sickle cell has been well-described. In a chart review of 46 patients with
sickle cell disease, hyponatremia was observed in 52% of cases [2]. The authors concluded that this finding
was likely secondary to a renally mediated water and salt-wasting state. However, we note that many
patients in this report did indeed have urine sodium and osmolality measurements consistent with SIADH.
Additionally, hyponatremia in the setting of lead toxicity has been described, but urine sodium and
osmolality measurements were not included in either of these reports, so no determination of SIADH could
be made [3,4]. The association of SIADH with lead toxicity was first proposed by Suarez et al. in 1992 [5].
They described a five-year-old patient with sickle cell anemia who had a BLL of 135 µg/dL. Her sodium
concentration declined from 145 mEqL to 114 mEq/L over four HDs, with urine osmolality and sodium
concentration consistent with SIADH. The patient had rapid improvement with fluid restriction, hypertonic
saline, and chelation. Issaivanan et al reported a similar case of a three-year-old child with sickle cell
anemia who had a BLL of 227 µg/dl, and an initial sodium concentration of 132 meq/L that decreased to 119
meq/L by day 3, also with urine sodium and osmolality consistent with SIADH [6].
 In a retrospective review of 480 patients with sickle cell disease, Ivascu et al. reported pica behavior in
14.8%-23.3% among those age 10-19 years old [7]. Issaivanan et al. reported a prevalence of pica to be 76%
in younger children [6]. Jung et al. noted multiple additional risk factors for young children to develop lead
poisoning including lower socioeconomic status, black race, and Hispanic ethnicity [8]. In addition, an
incomplete blood-brain barrier allows for increased lead penetration to the developing brain [8]. Patients
with sickle cell anemia more commonly have iron deficiency anemia, which leads to increased
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gastrointestinal absorption of lead [8,9].
The patient we describe here developed SIADH in the setting of both lead toxicity and fluoroquinolone
administration. An association between fluoroquinolones and SIADH has been reported previously [10-12].
It is difficult to establish a causal association between fluoroquinolones and SIADH in these case reports
given the use of other medications or other underlying disease states that may also be associated with
SIADH or hyponatremia. In vitro models have suggested fluoroquinolones are agonists at the N-methyl-D-
aspartate (NMDA) receptor [13]. Antidiuretic hormone (ADH) neurosecretory cells are primarily located in
the periventricular nucleus (PVN) and supraoptic nucleus (SON) of the hypothalamus, and glutamate has
been identified as an important neurotransmitter governing the release of ADH via both ionotropic non-
NMDA and NMDA receptors [14,15]. In vitro studies suggested that both non-NMDA and NMDA receptor
activation were necessary for stimulation of ADH release (Morsette) [15]. However, more recent in vivo
evidence reveals that ADH release in both the SON and PVN results from primary activation of non-NMDA
glutamate receptors [14]. Interestingly, PVN ADH release appears to be dependent on not only non-NMDA
receptor activation but also NMDA receptor inhibition [14]. Although the neuroregulation of ADH likely
involves more than glutamate receptor interactions, these receptors may be pertinent in the setting of both
fluoroquinolone use and lead toxicity.
Conclusions
This case of a three-year-old female with sickle cell anemia and pica who developed SIADH in the context of
concomitant lead toxicity and a urinary tract infection treated with a fluoroquinolone demonstrates that
hyponatremia may be multifactorial. SIADH may be associated with severe lead poisoning and may be more
likely among high-risk patients with sickle cell anemia, particularly where medications associated with
hyponatremia are involved. Where multiple risk factors for SIADH are present, evaluation for this disease
process should be undertaken in patients who develop hyponatremia. Lead toxicity should be considered in
patients with risk factors such as sickle cell anemia, pica, lower socioeconomic status, and non-specific
presenting features such as gastrointestinal distress.
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